Via Bonanno, 6
Tel ++39 050 2219603
Fax ++39 050 2210680
Click to download CV
Giulio Poli was born in San Miniato (Pisa) in June 1987.
He graduated with top marks (110/110 cum laude) in Medicinal Chemistry (5-year degree course) in 2012 at the Faculty of Pharmacy, University of Pisa (Italy).
In the same year, he won a 3-year PhD fellowship in Science of Drug and Bioactive Substances at the same University, and in 2016 he obtained an International PhD degree in Medicinal Chemistry.
Between 2014 and 2015, he spent a research period of more than a year as a Visiting PhD student in the research group of Professor Thierry Langer, at the Chemoinformatik Labor of the Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna (Austria).
In 2016, after obtaining his PhD, he won a research fellowship for computational studies on antiviral compounds at the Department of Biotechnology, Chemistry and Pharmacy, University of Siena (Italy). He worked as a Post-Doctoral Researcher in the group of Professor Maurizio Botta on the identification of novel Zika virus inhibitors within the context of the ZIKAlliance international research consortium.
In 2018 he obtained a Research Scientist position in Medicinal Chemistry at the Department of Pharmacy, University of Pisa (Italy) and started working as a Computational Medicinal Chemist at the Molecular Modeling and Virtual Screening Laboratory.
He participated in the development and managment of both national and international funded projects, e.g. PRONAT, for the identification of bioactive agents from natural products, in colaboration with CNCCS and IRBM Science Park; UNAVIR, for the identification of broad spectrum antiviral compounds; ZIKAlliance, an international consortium counting more than 50 partners in which he contributed to the identification of novel active compounds against Zika virus.
At present, he published 35 papers in international scientific journals and he participated as a speaker in various national and interational workshops and congresses. He is currently Associate Editorial Board Member of the journal Current Enzyme Inhibition.
Development of efficient VS protocols and innovative computational procedures for the identification of hit/lead compounds of various protein targets, ligand binding mode prediction and energetic/mechanicistic analyses, lead and hit-to-lead optimization studies.